Levodopa-induced dyskinesia: review, observations, and speculations.
about
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic ImplicationsTranscranial direct current stimulation (tDCS) for improving health -related quality of life, disability and impairment in patients with idiopathic Parkinson's diseaseRasagiline for levodopa-induced motor complications in ParkinsonĀ“s diseasePiribedil for levodopa-induced complications in Parkinson's diseasePiribedil versus levodopa in early Parkinson's diseaseDeep brain stimulation of subthalamic nucleus for Parkinson's diseaseLocomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathwayTranscranial direct current stimulation (tDCS) for idiopathic Parkinson's diseaseDeep brain stimulation of subthalamic nucleus for Parkinson's diseaseStriatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic DrugsWorsening of levodopa-induced dyskinesias by motor and mental tasksThe alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's diseaseAlterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPASpatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors.Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey.Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia.Ropinirole and pramipexole, the new agonists.A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.Reverse microdialysis of a 5-HT2A receptor antagonist alters extracellular glutamate levels in the striatum of the MPTP mouse model of Parkinson's disease.Pharmacotherapy for advanced Parkinson's disease.ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease.Idiopathic Parkinson's disease: epidemiology, diagnosis and management.Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.Clinical spectrum of levodopa-induced complications.Pramipexole for the treatment of early Parkinson's disease.Digital Health Revolution: Is it Time for Affordable Remote Monitoring for Parkinson's Disease?Anticonvulsant-induced dyskinesia.An ambulatory dyskinesia monitor.Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease.Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.Cannabinoids and value-based decision making: implications for neurodegenerative disorders.The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.Evaluation of cardiovascular risk in patients with Parkinson disease under levodopa treatmentUnilateral vs. bilateral STN DBS effects on working memory and motor function in Parkinson diseaseManagement of motor complications in advanced Parkinson's disease.Effects and molecular mechanism of chitosan-coated levodopa nanoliposomes on behavior of dyskinesia rats.Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?Managing the critical problems of advanced Parkinson's disease.Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia.
P2860
Q21129423-04AC9123-D4A9-4CF0-868D-E36F6AAC648BQ24201496-45D03BDD-A100-4F50-BFAC-ED19CB38EF6FQ24243502-A3D58886-70C5-4B13-AE99-C8A37A41EEDBQ24244549-CF56FDF1-7D3E-48C6-A4EB-C2F902FC3898Q24244961-CB3C7D5F-A5A7-4E1C-A498-CEE8EAC1D414Q24247833-49C9D0E6-588B-4577-AB93-35A856E91CF5Q24671046-B034F351-BB34-4589-8E83-2DCAD7A7EE16Q26471077-EFBD9C5F-0AF2-4FF4-817D-C2825D66677DQ26471357-4600BBAF-1F51-4E9E-949E-216229220C68Q26768220-1A1DB777-42CB-4AB1-8FF6-5179DA467836Q27300104-AE588DA9-7B10-406C-80B7-8E6F76CC85AFQ28372142-EB5DE926-87A3-4BD9-B7AF-36803BBCC55DQ28373127-D72680C3-895C-4CA5-8268-720719FC786AQ28376621-83DC8902-6EBE-4413-A139-B9931E629B31Q30594829-0EA22508-146C-47BB-8E2F-CEBAD2C1B230Q32061819-895242E9-A969-4E6F-98A5-C1FE726FC28DQ33285975-EB654FEF-A028-459C-89A2-A1FA24708711Q33714127-12E342B5-66E8-4A5F-9FA6-7786D551417DQ33733049-BDFB95C8-E6BF-49B6-AF6A-349C2FF36707Q33763197-AA54F55B-5600-49F6-B136-E022C4BFCA4DQ33821336-8D54BC47-5634-4E36-A0E7-5D93D3A085C8Q33864253-F085B346-A0D5-49FC-82BD-2ECF9CB5BF6FQ34053847-60782DEB-A71B-487D-8C7F-E7297AC54291Q34094008-6FBE02D4-8183-41AC-8724-CF6E43875FE4Q34452721-8D4D379B-E27F-476C-9EE6-4F474AE2BFDEQ34630735-CAC88A09-1E54-45F4-AD01-6CA97D0C3F32Q35124368-4A5D0F6C-5290-46BE-B93B-04FEE4C2FF30Q35194353-8DEB5023-FA6C-4AFE-BA5F-1B034C0228FDQ35454997-BB200195-AEC5-4FBE-A7E4-507D11798F70Q35821201-4C33B5C5-76E6-4642-8B8B-12DA268B9986Q36318159-A1827C07-7363-467B-B0FB-DE9ED4551C96Q36393644-EA78B60E-4DA7-46D9-87BD-AFAA5EA1C0D7Q36521884-2AEE1CF8-A66F-4FD5-95A3-874C0D3A19EEQ36578455-C11D8449-F25B-4781-8B62-B07CDCCF9A2DQ36593559-190C9965-6A94-469C-99B3-00E1E1BD15C9Q37050649-01A5E967-391F-41BD-927F-0D8A8111B020Q37064567-C5077F85-5AC2-4984-A32D-8619FCC18B33Q37506507-0A19D595-5D43-49E7-8E8D-C3FC6FA8167FQ37610215-E84EF16D-C165-4495-B9D7-70145BA3F253Q37674269-A3E96FA2-060B-43CC-B0F6-B5B5CFE48A71
P2860
Levodopa-induced dyskinesia: review, observations, and speculations.
description
1990 nĆ® lÅ«n-bĆ»n
@nan
1990幓ć®č«ę
@ja
1990幓å¦ęÆęē«
@wuu
1990幓å¦ęÆęē«
@zh-cn
1990幓å¦ęÆęē«
@zh-hans
1990幓å¦ęÆęē«
@zh-my
1990幓å¦ęÆęē«
@zh-sg
1990幓åøč”ęē«
@yue
1990幓åøč”ęē«
@zh
1990幓åøč”ęē«
@zh-hant
name
Levodopa-induced dyskinesia: review, observations, and speculations.
@en
type
label
Levodopa-induced dyskinesia: review, observations, and speculations.
@en
prefLabel
Levodopa-induced dyskinesia: review, observations, and speculations.
@en
P356
P1433
P1476
Levodopa-induced dyskinesia: review, observations, and speculations.
@en
P2093
P304
P356
10.1212/WNL.40.2.340
P407
P577
1990-02-01T00:00:00Z